Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1203 studies found for:    Open Studies | "Leukemia"
Show Display Options
Rank Status Study
1 Recruiting Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Condition: Leukemia
Interventions: Drug: ATRA;   Drug: ATO;   Drug: GO (Gemtuzumab ozogamicin);   Drug: Methylprednisolone
2 Recruiting Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Realgar-Indigo naturalis formula;   Drug: all-trans retinoic acid;   Drug: Arsenic trioxide;   Drug: Hydroxyurea
3 Recruiting Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia
Condition: Leukemia
Intervention: Biological: CD19-targeted CAR-T cells
4 Recruiting Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Condition: Leukemia
Intervention: Drug: Ara-c
5 Recruiting Proteasome Inhibition in Acute Promyelocytic Leukemia
Condition: Relapsed Acute Promyelocytic Leukemia
Intervention: Drug: Bortezomib
6 Recruiting Samples From Leukemia Patients and Their Donors to Identify Specific Antigens
Condition: Leukemia
Intervention:
7 Recruiting Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Tretinoin;   Drug: Mitoxantrone;   Drug: Mercaptopurine;   Drug: Methotrexate
8 Recruiting Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
Condition: Leukemia
Interventions: Drug: Bortezomib;   Drug: Pravastatin
9 Recruiting B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging
Condition: Chronic Lymphocytic Leukemia
Intervention:
10 Recruiting Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: ATRA;   Drug: ATRA + IDA
11 Recruiting French Registry of First-line Treatment of Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Intervention:
12 Recruiting A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Ibrutinib
13 Recruiting 2CDA With Rituximab in Hairy Cell Leukemia
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
14 Recruiting Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
Condition: Leukemia
Interventions: Drug: Decitabine;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Clofarabine
15 Recruiting Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine;   Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
16 Not yet recruiting A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Other: Standard Leukemia Care;   Other: Palliative Care
17 Recruiting Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia
Condition: Leukemia
Interventions: Drug: Fludarabine;   Drug: Clofarabine;   Drug: Busulfan;   Drug: SAHA;   Procedure: Stem Cell Infusion (SCT);   Drug: Thymoglobulin
18 Recruiting Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Condition: Leukemia
Interventions: Drug: Busulfan;   Drug: Clofarabine;   Drug: Gemcitabine;   Drug: Thymoglobulin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Filgrastim;   Drug: Tacrolimus;   Drug: Methotrexate
19 Recruiting Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Cladribine s.c. injection, HCL treatment
20 Recruiting Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Condition: Leukemia
Interventions: Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.